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To the Editor: Block et al.1 report in their open-label trial
that ‘use of calcium containing phosphate binders resulted in
more rapid progression of coronary calcium than did use of
sevelamer’. However, their trial could not explain the
mechanism whereby treatment with calcium-containing
phosphate binders increases coronary artery calcium scores
(CACS). Importantly, their patients with zero calcification at
baseline did not progress despite calcium loading. Moreover,
they found no relationship between the actual calcium load
and the severity of progressive calcification. They speculate
that progression of calcification is related to unsubstantiated
adynamic bone disease in calcium-treated patients. However,
a more likely explanation for the difference in CACS is the
significantly lower low-density lipoprotein and total cho-
lesterol level in sevelamer-treated patients. This view is
supported by their important, but not previously reported
finding in dialysis patients of a significant correlation
between the low-density lipoprotein and total cholesterol
levels and the change in CACS.
Reduction in low-density lipoprotein and total cholesterol
levels is known to lead to attenuation or even regression of
CACS.2 Progression of CACS can be reduced from 25–30%
annual increase to a 0–9% annual increase with low-
density lipoprotein cholesterol level reduction with statin
therapy.3 Unfortunately, the design of this and previous
studies1,4 failed to control for cholesterol levels, and there-
fore, their conclusions regarding the role of calcium load in
progression of CACS must be considered speculative. It
remains to be seen whether comparable amelioration of
CACS can be achieved by using the more cost-effective
combination of calcium-containing phosphate binders and
statin therapy.
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Effect of dietary modification
on urinary stone risk factors
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To the Editor: Pak et al. retrospectively studied 951 stone
formers and demonstrated reductions in urinary calcium
excretion and urinary saturation of calcium oxalate following
a diet limited in calcium, oxalate, sodium, and meat
products. They suggest that calcium stone formers with
urinary calcium 46.88 mmol/day restrict their dietary
calcium intake to 10 mmol/day.1
We disagree with this recommendation. In a 5-year
randomized trial, Borghi et al. compared a low-calcium diet
(10 mmol/day) to a diet without calcium restriction but low
in salt and animal protein in 120 calcium oxalate stone
formers with hypercalciuria (mean urinary calcium 11 mmol/
day).2 The relative risk of stone recurrence in the usual
calcium group, compared to the restricted calcium group,
was 0.49 (P¼ 0.04). Although this study did not address the
independent role of dietary calcium restriction, it assessed
actual kidney stone formation as the primary outcome rather
than surrogate measures such as urinary saturation. In
addition, secondary analyses of this trial confirmed the
powerful effect of dietary sodium and animal protein
restriction on reducing urinary calcium excretion.
We remain concerned about the safety of dietary calcium
restriction alone in patients with idiopathic hypercalciuria.
Only a fraction of dietary calcium is absorbed.3 Consump-
tion of 10 mmol/day of calcium in a patient with urinary
calcium losses of 6.5 mmol/day (the mean value from Pak’s
current study) may result in negative calcium balance and,
over time, reduced bone mass.
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